# Female Pattern Hair Loss (FPHL): Causes, Stages & Treatment

> Female pattern hair loss is the most common cause of hair loss in women.

*Female pattern hair loss (FPHL), also called androgenetic alopecia, is the leading cause of hair loss in women, affecting roughly 40% by age 50 and over 50% by age 79. It causes progressive, non-scarring miniaturization of hair follicles concentrated on the crown and top of the scalp with the frontal hairline typically preserved. Diagnosis is primarily clinical, supported by dermoscopy. Topical minoxidil (2% or 5%) is the only FDA-approved treatment; oral minoxidil, spironolactone, and finasteride are used off-label with moderate evidence.*

- Canonical: https://beautycomparison.com/female-pattern-hair-loss-guide
- Reviewed: 2026-06-20
- Publisher: Beauty Comparison (Beauty Comparison Editorial) — independent, brand-neutral

## Key takeaways
- FPHL is the most common cause of hair loss in women, affecting an estimated 40% of women by age 50 and more than 50% by age 79.
- The hallmark is progressive miniaturization of hair follicles concentrated on the crown and central parting, with the frontal hairline typically preserved — unlike male pattern baldness.
- Most women with FPHL have normal androgen levels; the condition reflects increased follicular sensitivity to androgens rather than true hyperandrogenism.
- Topical minoxidil (2% or 5%) is the only FDA-approved treatment and remains the evidence-based first choice; roughly 60% of users see meaningful improvement.
- Off-label oral minoxidil (0.25–2.5 mg daily), spironolactone, and higher-dose finasteride show promising results but require physician supervision.
- All treatments require at least 6–12 months before efficacy can be assessed, and benefits are lost if treatment is stopped — FPHL has no cure, only management.
- Early diagnosis and treatment maximize the chance of preserving existing hair; once follicles fully miniaturize, regrowth is unlikely.

## What Is Female Pattern Hair Loss?

Female pattern hair loss (FPHL) — also called androgenetic alopecia in women — is a chronic, non-scarring progressive thinning of the scalp that follows a characteristic central pattern. It is the most common cause of hair loss in women worldwide, and unlike many causes of shedding, it does not resolve without treatment.

FPHL is distinct from male pattern baldness in its distribution. While men typically lose hair from the temples and vertex, women experience diffuse thinning concentrated on the crown and central part of the scalp, with the frontal hairline usually — though not always — preserved. Visible baldness (complete denudation) is rare in women; the more common complaint is an increasingly visible scalp through thinning hair, a widening part line, or a ponytail that has measurably reduced in circumference.

The condition is under-recognized. Many women attribute early FPHL to stress, diet, or normal aging and delay seeking evaluation. This matters because early treatment — when follicles are miniaturising rather than lost — produces better outcomes.

---

## How Common Is It?

FPHL is far more prevalent than most people realise:

- Approximately **12% of women** show clinically detectable FPHL by age 29.
- Around **40% of women** have signs of hair loss by age 50.
- More than **50% of women** are affected by age 79.
- Fewer than **45% of women** maintain a full head of hair throughout life.
- In the United States alone, an estimated 21 million women are affected.
- Prevalence is highest in Caucasian women, followed by Asian and African American women.

The condition can begin in the late teens or twenties, with incidence rising sharply around menopause — a period when the protective effect of estrogen diminishes and androgen sensitivity becomes more apparent.

---

## Causes and Pathophysiology

### The Role of Androgens

The name "androgenetic alopecia" reflects two core drivers: androgens (hormones) and genetics (heredity). However, the relationship with androgens in women is more nuanced than in men.

In men, dihydrotestosterone (DHT) — a potent androgen produced when 5-alpha-reductase converts testosterone — directly shortens the anagen (growth) phase and miniaturises hair follicles. In women, **most patients with FPHL have completely normal androgen levels**. What differs is the follicle's sensitivity to normal circulating androgens. Women's scalp hair follicles in genetically susceptible zones have a greater density of androgen receptors and respond more aggressively to the same hormonal signal that leaves unaffected follicles unchanged.

A minority of women with FPHL do have elevated androgens — this is why dermatologists screen for signs of hyperandrogenism (irregular periods, acne, hirsutism, polycystic ovary syndrome) in women presenting with FPHL, particularly before menopause.

### What Happens to the Follicle

The biological sequence in FPHL is follicular miniaturisation:

1. **Shortened anagen phase:** The active growth phase of the hair cycle progressively shortens from several years to just months.
2. **Extended telogen phase:** The resting/shedding phase lengthens relative to growth.
3. **Miniaturised fibers:** Each successive hair cycle produces a thinner, shorter, less pigmented hair — a process that transforms terminal (pigmented, thick) hairs into vellus-like (colorless, fine) hairs that barely emerge above the scalp surface.
4. **Follicular atrophy:** Over years, affected follicles atrophy entirely, creating the smooth, thinned appearance of advanced FPHL.

Genetics is polygenic — there is no single "baldness gene," and inheritance can come from either parent, explaining why FPHL often does not follow a simple family pattern.

### Other Contributing Factors

FPHL can be precipitated or accelerated by:

- **Hormonal transitions:** Menopause, postpartum (when pregnancy's estrogen-protective effect withdraws), stopping oral contraceptives with androgenic progestogens
- **Medical conditions:** Thyroid disorders, iron deficiency anemia, PCOS — these don't cause FPHL but can worsen diffuse shedding and should be investigated and treated
- **Medications:** Certain androgenic progestogens, anabolic steroids, and some antihypertensives

---

## How FPHL Looks: Patterns and Stages

### The Ludwig Classification

The Ludwig scale (1977) remains the most widely used staging system for FPHL:

- **Ludwig Grade I (Mild):** Perceptible thinning of the crown, limited to an area 1–3 cm behind the frontal hairline. The part line is noticeably wider, but overall density loss may be subtle on cursory inspection. The frontal hairline is fully preserved.
- **Ludwig Grade II (Moderate):** Pronounced thinning across the crown, clearly visible on the central scalp. The diffuse density reduction is obvious and the part appears strikingly wide.
- **Ludwig Grade III (Severe/Advanced):** Near-complete or complete thinning across the area defined by Grades I and II, with visible scalp. This affects fewer than 1% of women.

**Important caveat:** By the time a woman presents at Ludwig Grade I, she has already lost a significant proportion of hair density. The Ludwig scale captures what is visible, not the biological progression that preceded it. Early-stage FPHL often goes unrecognised until 50% or more of hair density in the affected zone has been lost.

Other scales — the Sinclair (5-point) and Savin (8-stage) scales — offer finer gradations, particularly for monitoring treatment response over time.

### Distribution Subtypes

Three distributional patterns are recognized in women:

- **Ludwig (diffuse centroparietal) type:** The classic pattern — diffuse thinning of the crown and central scalp with hairline preservation. The most common presentation.
- **Christmas tree (Olsen) pattern:** Thinning that is wider at the front and tapers towards the vertex, creating a triangular shape resembling an inverted Christmas tree. Sometimes confused with frontal fibrosing alopecia.
- **Hamilton (bitemporal) pattern:** Resembles male pattern hair loss with frontal recession; less common and often associated with hyperandrogenism.

---

## Diagnosis

Diagnosis of FPHL is primarily clinical — a detailed history and careful physical examination by a dermatologist are usually sufficient. Key elements include:

### Clinical History
- Age of onset and rate of progression
- Family history of hair loss (maternal or paternal)
- Menstrual regularity, recent pregnancies, hormonal changes
- Medications (especially androgenic progestogens, corticosteroids)
- Dietary restrictions or recent significant weight loss
- Recent illness, surgery, or severe psychological stress

### Physical Examination
The dermatologist examines the distribution and density of hair loss. A **hair pull test** is performed — gently grasping 40–60 hairs between thumb and forefinger and applying steady traction. In active FPHL, up to 6 telogen hairs may be extracted. In associated telogen effluvium, the count is higher across multiple scalp zones.

### Dermoscopy (Trichoscopy)
Scalp dermoscopy is highly useful and has become standard of care. Features of FPHL on dermoscopy include:
- **Hair shaft diameter variability:** More than 20% of hairs showing significant diameter variation is a key diagnostic criterion
- **Increased vellus hairs:** Fine, short, unpigmented hairs replacing terminal hairs
- **Peripilar sign:** A brown halo around the follicular ostium in some cases
- **Reduced follicular unit density** in the central versus the occipital scalp

### Laboratory Investigations

Routine bloods are recommended to exclude treatable contributing factors, particularly in younger women or those with associated symptoms:

- **Full blood count:** Iron deficiency anemia is a common cause of increased shedding that can overlay FPHL
- **Ferritin:** The most sensitive marker of iron stores; low ferritin (<30–40 μg/L) impairs the hair cycle even without frank anemia
- **Thyroid function (TSH):** Both hypothyroidism and hyperthyroidism cause diffuse hair loss
- **Free testosterone, DHEAS, prolactin:** Indicated if signs of hyperandrogenism are present (irregular periods, acne, hirsutism)

### Scalp Biopsy

Biopsy is reserved for diagnostically uncertain cases. Horizontal sectioning of two 4-mm punch biopsies from affected scalp reveals:
- A **terminal-to-vellus hair ratio** below 4:1 (normal >8:1) is diagnostic of FPHL
- A ratio of 4:1 to 8:1 suggests an indeterminate picture, often with co-existing telogen effluvium

---

## Treatment

### The Evidence Hierarchy

| Treatment | Regulatory Status | Evidence Level |
|---|---|---|
| Topical minoxidil 2%/5% | FDA-approved (women) | Moderate — multiple RCTs |
| Oral minoxidil 0.25–2.5 mg | Off-label | Moderate — growing RCT data |
| Spironolactone 25–200 mg | Off-label | Moderate — RCTs and cohort studies |
| Finasteride 2.5–5 mg | Off-label | Limited — no benefit at 1 mg; uncontrolled data at higher doses |
| Dutasteride 0.5 mg | Off-label | Limited |
| PRP therapy | Investigational | Moderate but heterogeneous |
| Low-level laser therapy | FDA-cleared (device) | Moderate, limited long-term data |
| Hair transplantation | Established surgical technique | Case series; good outcomes in suitable candidates |

### Topical Minoxidil

Topical [minoxidil](/[minoxidil](/minoxidil-women-guide)-women-guide) is the cornerstone of FPHL treatment and the only FDA-approved medication for this indication. It is a potassium channel opener that prolongs the anagen phase, increases blood flow to the follicle, and stimulates follicular miniaturisation to reverse.

- **Concentration:** 2% solution (twice daily) and 5% foam (once daily) are both effective. Clinical trials show no statistically significant difference in efficacy between concentrations, but 5% once-daily foam has compliance advantages.
- **Onset:** Visible improvement typically begins at 4–6 months. A **temporary increase in shedding** during the first 2–8 weeks is common and does not indicate treatment failure — it reflects old telogen hairs being pushed out by the anagen stimulation.
- **Efficacy:** Pooled trial data show approximately twice as many women achieve moderate-to-marked regrowth with minoxidil versus placebo. Mean hair count improvements of 13–20 hairs/cm² are reported across studies. However, roughly **40% of patients see little or no benefit**.
- **Duration:** Treatment must be continued indefinitely. Stopping minoxidil leads to loss of any gained hair within 3–6 months, returning to the pre-treatment baseline.
- **Contraindications:** Not to be used in pregnancy or breastfeeding. Avoid in women with scalp [psoriasis](/psoriasis-skin-guide) or skin conditions that may increase absorption. Hypertrichosis (unwanted facial or body hair growth) occurs in some women, typically resolving on switching to foam formulation or using the frontal scalp.

### Oral Minoxidil

Low-dose oral minoxidil (0.25–2.5 mg daily) has emerged as a highly practical alternative for women who struggle with topical application or experience contact dermatitis from minoxidil vehicles. Clinical data show hair density increases of 20–27 hairs/cm² at doses of 1 mg daily — numerically superior to the topical form in several head-to-head comparisons. In a 2025 international Delphi consensus, low-dose oral minoxidil was endorsed as a practical option after topical treatment.

Common side effects: hypertrichosis (54%), headache (10%), and peripheral edema (9%). Spironolactone co-prescription reduces edema risk. Oral minoxidil is not FDA-approved for hair loss; it requires a prescription and clinical monitoring.

### Anti-Androgen Therapies

#### Spironolactone
Spironolactone is an aldosterone antagonist with anti-androgenic properties, used at 25–200 mg daily for FPHL. One randomised controlled trial demonstrated equivalent efficacy to cyproterone acetate; approximately 44% of users in clinical studies show photographic improvement. Common side effects include menstrual irregularity, fatigue, and postural hypotension.

**Contraindicated in pregnancy** (teratogenic to male fetuses) and in women with renal insufficiency or hyperkalaemia. Pregnancy prevention is mandatory while using spironolactone.

#### Finasteride
Finasteride (a 5-alpha-reductase inhibitor) at 1 mg daily — the dose approved for men — showed **no significant benefit** in postmenopausal women in a large, double-blind, placebo-controlled multicentre trial. However, higher doses of 2.5–5 mg have shown improvement in uncontrolled studies, with 62–81% reporting photographic improvement. It remains off-label and must not be used in premenopausal women of childbearing potential due to teratogenicity risk.

#### Dutasteride
Dutasteride inhibits both Type 1 and Type 2 5-alpha-reductase and may be more potent than finasteride, but evidence in women is limited to small uncontrolled studies.

### Platelet-Rich Plasma (PRP)

PRP therapy involves drawing a patient's blood, concentrating the platelet-rich fraction via centrifugation, and injecting it into the scalp. Platelets release growth factors (PDGF, VEGF, IGF-1) that may stimulate follicular activity. A meta-analysis found mean hair density increases of approximately 36.8 hairs/cm² with PRP treatment. However, studies are heterogeneous in terms of protocol, preparation technique, and outcome measurement. PRP is not FDA-approved for hair loss and carries a cost per session of several hundred to over a thousand US dollars.

### Low-Level Laser Therapy (LLLT)

FDA-cleared home-use laser combs and caps deliver red light at 650 nm wavelength to the scalp, theoretically stimulating follicular activity via photobiomodulation. Objective hair-count studies show modest improvements (approximately 17 additional hairs per cm²), though subjective ratings by users often do not differ from sham devices. LLLT is a low-risk, lower-evidence adjunct — not a replacement for pharmaceutical therapy.

### Hair Transplantation

Follicular unit extraction (FUE) or follicular unit transplantation (FUT) are established surgical options for appropriately selected women with FPHL. The major requirement is an adequate donor area — typically the occipital (back of head) scalp — that has not been affected by androgenetic miniaturisation. Hair transplantation does not treat the underlying process; it redistributes hair follicles. Medical treatment should continue post-transplant to prevent loss of native hairs.

---

## The Psychological Impact

Hair loss causes significant psychological distress in women, often to a degree underestimated by clinicians. Research documents correlations with negative body image, reduced social functioning, depression, and diminished self-esteem. Notably, **52% of women** report feeling "very to extremely upset" by hair loss, compared to 28% of men. Acknowledging this impact and, where appropriate, referring for psychological support or peer resources is part of comprehensive care.

---

## When to See a Dermatologist

See a dermatologist if you notice:

- A widening center part that wasn't there before
- Visible scalp through thinner hair on the crown or top of the head
- Your ponytail noticeably thinner in circumference
- Sudden or significant increases in daily hair shedding (especially losing more than 100–150 hairs per day)
- Hair loss alongside irregular periods, acne, or unwanted facial or body hair (possible hyperandrogenism warranting investigation)
- Hair loss that began following pregnancy, stopping oral contraceptives, or other hormonal changes

Early evaluation matters. The window in which treatment can preserve existing follicles and potentially reverse early miniaturisation is much larger than most patients realise — but it closes as follicles atrophy permanently.

## FAQ
**What does the latest evidence say about treating FPHL in 2026?**

Topical minoxidil remains the only FDA-approved treatment and the first-line recommendation. The biggest development in recent years is the growing evidence base for low-dose oral minoxidil (0.25–2.5 mg daily), which a 2025 international consensus panel endorsed as a practical, effective option — with hair density gains numerically superior to topical application in several comparisons. JAAD published a clinical review in 2025 highlighting antiandrogen therapies (spironolactone, high-dose finasteride, bicalutamide) as useful second-line options particularly in women with signs of hyperandrogenism. No cure exists, but the treatment toolkit is meaningfully expanding.

**Can female pattern hair loss be reversed?**

Partially, in the early stages. Minoxidil and other treatments can extend the anagen phase and produce modest regrowth of miniaturised hairs in around 60% of users. However, once follicles have fully atrophied, recovery is not possible with current therapies. This is why early diagnosis matters enormously — treating miniaturising follicles is far more effective than attempting to reverse complete follicular loss. Most treatments slow or halt progression rather than produce dramatic regrowth.

**Is FPHL caused by stress or hormonal imbalance?**

FPHL is primarily genetic. Most women with the condition have completely normal hormone levels; the problem is that their scalp follicles are genetically more sensitive to normal concentrations of androgens. Stress and certain hormonal events (menopause, postpartum, stopping the pill) can accelerate or precipitate the onset of FPHL in genetically susceptible women, but they are not the root cause. Blood tests for thyroid function, ferritin, and androgens are routinely checked to rule out treatable contributing conditions, but a 'hormonal imbalance' alone rarely explains classic FPHL.

**How is female pattern hair loss different from male pattern baldness?**

The same biological process — androgen-driven follicular miniaturisation — underlies both conditions, but the pattern differs because women have lower circulating androgen levels and different follicular androgen-receptor density across the scalp. Men typically lose hair from the temples and vertex, often progressing to extensive baldness. Women lose density diffusely across the crown and top of the scalp, with the frontal hairline almost always preserved, and rarely progress to complete baldness. Women are also more likely to have normal serum androgens, whereas men with androgenetic alopecia usually demonstrate the typical DHT-driven response.

**How long does minoxidil take to work for women?**

A minimum of 4–6 months of consistent daily use is needed before judging efficacy, and 12 months is the standard endpoint in most clinical trials. Many women notice a temporary increase in shedding in the first 2–8 weeks — this is a recognized, expected response reflecting old telogen hairs being shed to make way for newly stimulated anagen growth. Stopping minoxidil during this phase is the most common mistake and leads to abandoning a potentially effective treatment. Peak benefit is typically reached at 12–18 months of continuous use.

**Does FPHL run in families?**

Yes. FPHL is polygenic — influenced by multiple genes inherited from either or both parents. A family history on either the maternal or paternal side increases risk, but inheritance is not deterministic. It is entirely possible to develop FPHL without an obvious family history, and equally possible to carry the genetic predisposition without ever experiencing significant hair loss — particularly if other protective hormonal factors are present.

## When to see a professional
See a dermatologist if you notice a widening part line, increasing scalp visibility on the crown, or a noticeably thinner ponytail — especially if these changes have appeared or progressed over months. Early evaluation is important because treatment is more effective while follicles are miniaturising rather than lost. Also consult a doctor promptly if hair loss is accompanied by irregular periods, acne, or unwanted facial or body hair (possible hyperandrogenism), if shedding is sudden or severe, or if over-the-counter minoxidil has been used for 12 months with no improvement. A dermatologist can diagnose FPHL, rule out other causes, and tailor treatment to your specific situation.

## Sources
- Female Pattern Hair Loss — PubMed Central / NIH (2014-01-01): https://pmc.ncbi.nlm.nih.gov/articles/PMC3968982/
- Female-pattern hair loss: therapeutic update — PubMed Central / NIH (2023-07-01): https://pmc.ncbi.nlm.nih.gov/articles/PMC10334345/
- Female pattern hair loss: Current treatment concepts — PubMed Central / Clinical Interventions in Aging (2009-01-01): https://pmc.ncbi.nlm.nih.gov/articles/PMC2684510/
- Interventions for female pattern hair loss — PubMed Central / Cochrane-style systematic review (NIH) (2019-05-01): https://pmc.ncbi.nlm.nih.gov/articles/PMC6457957/
- Female Pattern Hair Loss — AAD Patient Resource — American Academy of Dermatology: https://www.aad.org/public/diseases/hair-loss/types/female-pattern
- Androgenetic Alopecia — StatPearls — NCBI Bookshelf / NIH: https://www.ncbi.nlm.nih.gov/books/NBK430924/
- Female pattern hair loss — DermNet — DermNet NZ: https://dermnetnz.org/topics/female-pattern-hair-loss
- Antiandrogen therapy for the treatment of female pattern hair loss: A clinical review — Journal of the American Academy of Dermatology (2025-05-01): https://www.jaad.org/article/S0190-9622(25)00722-4/abstract

_Health information, not medical advice._